Neoehrlichia mikurensis is uncommon in rheumatological patients receiving tumour necrosis factor inhibitors and in blood donors: a retrospective cohort study
Authors' conclusion
N. mikurensis infection does not appear to represent a prevalent risk in Danish rheumatological patients receiving TNFi or in blood donors.
Study context
- Population
- Rheumatological patients receiving tumour necrosis factor inhibitors (TNFi) (Danish Rheumatological Biobank, DANBIO) and healthy blood donors (Danish Blood Donor Study), 2015–2022
- Participants
- 400 vs 400
- Exposure
- Rheumatological patients receiving TNFi and healthy blood donors
- TNFin = 400
- Blood donorsn = 400
- Outcome
- Prevalence of N. mikurensis (DNA by real-time PCR targeting groEL gene, one plasma sample per individual)
Main finding
As reported in the abstract
N. mikurensis DNA (real-time PCR targeting groEL gene)
- N. mikurensis DNA was not detected in any samples from patients or blood donors
Observational data: associations, not effects.
Original publication
Neoehrlichia mikurensis is uncommon in rheumatological patients receiving tumour necrosis factor inhibitors and in blood donors: a retrospective cohort study. RMD Open. Published 4 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →